Total cohort (n = 741) | cTNI elevation(n = 50) | cTNI negative(n = 691) | P* | P † | |
---|---|---|---|---|---|
Age (years); median (range) | 47.8 (17.5 –89.9) | 61.9 (21.6 – 88.1) | 46.8 (17.5 – 89.9) | <0.001 | 0.07 |
Gender | 0.77 | ||||
Female | 303 (40.9%) | 19 (38%) | 284 (41.1%) | ||
Male | 438 (59.1%) | 31 (62%) | 407 (58.9%) | ||
CK elevated on admission | 303 (40.9%) | 27(54%) | 276 (39.9%) | <0.001 | 0.002 |
Further subsequent CK increase after admission | 187 (25.2%) | 24 (48%) | 163 (23.6%) | <0.001 | |
Cr elevated on admission | 85 (11.5%) | 16 (32%) | 69 (10%) | 0.05 | 0.14 |
eGFR (ml/min/1,73 m2 body surface), median (range) | 76.9 (43.8 – 162.8) | 76.1 (45.9 – 162.8) | 76.9 (43.8 – 159.3) | 0.40 | |
Hypertension | 155 (20.9%) | 16 (32%) | 139 (20.1%) | 0.07 | |
Hypercholesterolemia | 117 (15.8%) | 12 (24%) | 105 (15.2%) | 0.11 | |
Diabetes | 75 (10.1%) | 9 (12%) | 66 (9.6%) | 0.08 | |
Intake of Beta-blocker | 92(12.4%) | 15(30%) | 77 (11.1%) | <0.001 | 0.63 |
Known CAD | 96 (13%) | 18 (36%) | 78 (11.3%) | <0.001 | 0.56 |
Vascular risk profile | 193 (33.9%) | 32(64%) | 161(23.3%) | <0.001 | 0.001 |
Regular alcohol consumption | 222 (30%) | 17 (34%) | 205 (29.7%) | 0.52 | |
Known epilepsy | 251 (33.9%) | 25 (50%) | 226 (32.7%) | 0.02 | 0.18 |
Symptomatic epilepsy | 249 (33.6%) | 23 (46%) | 226 (32.7%) | 0.06 | 0.52 |
Intake anticonvulsants | 231 (31.2%) | 23 (46%) | 208 (30.1%) | 0.02 | 0.34 |